&w=3840&q=100)
World Asthma Day 2025: India turns to smart tools to tackle high mortality
World Asthma Day 2025: As India battles rising asthma cases driven by pollution and lifestyle shifts, innovations in diagnosis, inhalers, and digital tools are redefining care
Barkha Mathur New Delhi
It's World Asthma Day 2025, and while millions across the globe are still learning to live with this chronic lung condition, India is seeing a shift in how asthma is understood and treated. From smart inhalers and digital health tools to better patient education, the country is inching closer to personalised, effective asthma care. But even as metros embrace smart tech and biologics, questions of access, awareness, and affordability still loom large, especially outside urban centres.
Why World Asthma Day 2025 matters more than ever
World Asthma Day, observed every year on the first Tuesday of May, is an initiative led by the Global Initiative for Asthma (GINA) to raise awareness and improve asthma care around the world. The theme for 2025, 'Make inhaled treatments accessible for all', emphasises the need for universal access to essential asthma medications.
India accounts for highest asthma deaths despite lower prevalence
According to GINA, asthma is one of the most common chronic non-communicable diseases that affects over 260 million people and is responsible for over 450,000 deaths each year worldwide.
In India, the asthma burden is particularly alarming. The country accounts for nearly 13 per cent of the global asthma prevalence and a staggering 46 per cent of global asthma-related deaths, according to the latest Global Burden of Disease 2021 Report. ALSO READ |
An April 2024 paper published in the PubMed Central journal at the US National Institutes of Health's National Library of Medicine explains that despite not having the highest number of asthma patients, India's mortality rate is disproportionately high due to underdiagnosis, poor disease control, and limited access to essential medications. A 2024 study noted that India's asthma-related mortality rate is three times higher than the global average, and the country also bears more than double the global burden in terms of disability-adjusted life years (DALYs).
These numbers aren't just statistics, they represent millions of people whose daily lives are disrupted due to poor air quality, smoking, misinformation, and limited access to specialised care.
'Asthma is becoming increasingly common in India, especially in the northern parts, due to high pollution levels and rising rates of smoking among adolescents,' says Dr Gyanendra Agrawal, Director of Respiratory & Critical Care Medicine, Max Super Speciality Hospital, Noida.
From diagnosis to drugs: India shifts to precision asthma treatment
Asthma care in India has seen a major evolution in recent years, with a shift from generic treatments to personalised, technology-driven approaches.
'India has seen a noteworthy shift in asthma care, moving from symptomatic relief to precision-driven management,' says Dr Arjun Khanna, Senior Consultant & Head, Pulmonology Department, Amrita Hospital, Faridabad. 'Advances like FeNO testing (or exhaled nitric oxide test) to determine lung inflammation, impulse oscillometry, high-resolution CT scans and biologics like anti-IgE (antibody that specifically targets immunoglobulin E) and anti-IL5 therapies (such as mepolizumab, benralizumab, and reslizumab, are monoclonal antibodies that target interleukin-5) have transformed how we diagnose and treat asthma.'
'These biologics have significantly helped difficult-to-treat asthma patients. They reduce flare-ups and decrease the need for steroids,' Dr Agrawal explains.
Asthma treatment cost in India: Biologics remain unaffordable for many
The cost of asthma treatment in India varies widely depending on the severity of the condition and the specific treatment approach. Annual expenses can range from ₹18,737 to ₹1,18,303, influenced by factors such as medication requirements and hospitalisation needs.
Asthma treatment costs
Treatment Type Estimated cost Notes
Standard Inhalers ₹380 – ₹1,100 Preventive inhalers; prices vary by brand and dosage.
Smart Inhalers ₹850 – ₹1,050 Advanced inhalers with features like dose counters.
Biologic Therapies ₹8,000 – ₹28,000 per dose Used for severe asthma; cost varies by medication type.
Doctor Consultation ₹500 – ₹2,000 per visit Fees depend on the healthcare facility and specialist.
Nebulizers (Home Use) ₹3,000 – ₹5,000 Devices for administering medication in mist form.
Bronchial Thermoplasty Up to ₹10,00,000 Advanced procedure for severe cases; available in select centers.
Smart inhalers and mobile apps improve medication adherence
Inhalers remain the backbone of asthma treatment, but their design and delivery mechanisms have significantly improved.
'Next-generation inhalers such as Dry Powder Inhalers (DPIs) ensure better drug delivery and patient compliance,' Dr Khanna explains. 'Smart inhalers with Bluetooth connectivity are also helping doctors and patients track usage and effectiveness in real-time.'
Dr Gyanendra Agrawal, Director–Respiratory & Critical Care Medicine, Max Hospital, Noida, agrees that modern tools are making asthma management easier and more effective. 'Mobile apps now allow patients to log symptoms, track peak flow rates, and receive reminders for medication,' Dr Agrawal says. 'This improves long-term adherence and allows doctors to adjust treatment based on real-world data.'
India's asthma tech advances still slow to reach rural populations
Despite these advances, a significant portion of India's population, especially in tier 2 and 3 cities and rural areas, still struggles with access.
'Urban centres have embraced advanced options, but tier 2 and 3 cities are catching up slowly,' Dr Khanna notes. 'Telepulmonology, mobile respiratory clinics, and government drug programs are beginning to bridge the gap.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
30-05-2025
- Business Standard
France to ban smoking in public spaces where kids are present from July 1
Starting July 1, France will ban smoking in public spaces like parks, beaches, and bus stops to protect children's health; violators may face fines up to 135 euros ($154) Barkha Mathur New Delhi France is saying 'non' to puffing in public where children are around. Starting this July, lighting up a cigarette at the beach or bus stop in France might land you a hefty fine. In a move hailed by health advocates, the French government is set to roll out tough new anti-smoking rules to keep public spaces, especially those frequented by children, smoke-free, according to media reports. Why is France banning smoking in outdoor public places? French Health and Family Minister Catherine Vautrin explained in an interview published by the regional Ouest-France daily on its website that tobacco 'must disappear where there are children.' She added, 'The decision is rooted in public health, particularly for children. The freedom to smoke stops where children's right to breathe clean air starts.' The restrictions will take effect on July 1 and will cover all outdoor areas where children are likely to be present, including beaches, parks, public gardens, school surroundings, bus stops, and sports venues, she said. According to Santé Publique France (Public Health France), the French national public health agency reporting to the Ministry of Health, about 75,000 people die from tobacco-related complications each year in the country. The government wants to take stronger steps to reduce this number and ensure that children are not exposed to secondhand smoke in open, public areas. Where will smoking be banned under the new rules? Public parks and gardens Beaches School surroundings Sports stadiums and grounds Bus and tram stops The aim is to create tobacco-free zones in all places where children and families gather. What is the penalty for breaking France's new smoking ban? If you're caught smoking in a restricted outdoor area, you could face a fine of up to €135 ($154). French authorities plan to actively enforce the new rules, with signage and public awareness campaigns to support compliance. Are there exceptions to the smoking ban in France? There are two notable exceptions: Café terraces are exempt, meaning adults can still smoke while sipping coffee outside a café Electronic cigarettes (e-cigarettes or vapes) are not included in this ban, though France is working on tightening vaping regulations soon Do French citizens support the outdoor smoking ban? According to a survey cited by news agency AFP, 62 per cent of French citizens support a ban on smoking in public spaces. That's nearly two out of three people. How widespread is smoking in France today? According to a report by the French Observatory of Drugs and Addictive Behaviours, a non-profit organisation that collects data on drug use and addiction and evaluates public policy, smoking is declining in the country, particularly among teens. It found that daily smoking among 17-year-olds has dropped by nearly 16 percentage points since 2011. However, vaping is becoming more common, with 56.9 per cent of 17-year-olds having tried it at least once. France joins global efforts to tighten tobacco laws France is joining a growing list of countries stepping up their tobacco control measures. Spain recently proposed expanding its own smoking bans to include terraces, university campuses, and open-air nightclubs. The UK is banning all single-use disposable vapes starting June 1 and is debating further restrictions on smoking in public spaces. For more health updates, follow #HealthWithBS
&w=3840&q=100)
Business Standard
21-05-2025
- Business Standard
New WHO agreement on pandemic response: What's it is and what it will do
With lessons from Covid-19, WHO members back treaty to improve equity, vaccine access, and emergency coordination during future outbreaks Barkha Mathur New Delhi World Health Organization (WHO) member states have adopted a landmark agreement aimed at addressing the gaps exposed during the Covid-19 pandemic. The WHO Pandemic Agreement is designed to ensure faster, fairer and more coordinated global responses during future health emergencies. What is the WHO Pandemic Agreement? The WHO Pandemic Agreement is the first legally binding international accord to comprehensively address pandemic prevention, preparedness, and response. Adopted under Article 19 of the WHO Constitution, it promotes data sharing, equitable access to resources and greater cooperation between countries during health crises. The agreement text states that member countries recognise 'that the international spread of disease is a global threat… that calls for the widest possible international and regional collaboration… while reaffirming the principle of the sovereignty of States in addressing public health matters.' What are the goals of the WHO pandemic treaty? The agreement outlines five primary objectives: Ensure equitable access to pandemic-related vaccines, treatments, and diagnostics Strengthen collaboration through data and pathogen sharing Support resilient health systems, especially in low-resource settings Promote knowledge and technology transfer for local production Establish sustainable funding mechanisms for rapid response How will countries benefit from the pandemic agreement? Countries that sign and ratify the agreement will be entitled to: Rapid access to 20 per cent of global pandemic-related health product output — 10 per cent as donations, 10 per cent at affordable prices A Global Supply Chain and Logistics Network (GSCL) for fair resource distribution A coordinated financial mechanism for emergency response from day one of a pandemic Access to shared technologies and production knowledge, especially in developing countries What is the WHO Pathogen Access and Benefit-Sharing System (PABS)? The Pathogen Access and Benefit-Sharing System (PABS), still under negotiation, will govern how countries share biological materials and genome sequences and ensure fair return benefits like vaccines and diagnostics. The PABS annex will be finalised for consideration at the 2026 World Health Assembly. The treaty also adopts a 'One Health' approach, acknowledging the link between human, animal and environmental health. What happens next? The agreement is now open for signature and ratification. It will become binding once ratified by 60 countries. Member states are expected to: Begin aligning national laws with the agreement Engage in the development of the PABS annex Support WHO-led efforts to strengthen health systems, particularly in developing nations Consider early ratification to expedite the treaty's entry into force How will the agreement promote equity in vaccine distribution? The agreement directly addresses vaccine inequity, a major issue during the Covid-19 pandemic. Pharmaceutical manufacturers will be required to reserve: 10 per cent of production for WHO-led donations 10 per cent at reduced prices for distribution to low-income nations The agreement also discourages vaccine hoarding and promotes timely and transparent supply allocation to vulnerable populations. What did WHO say about the significance of the treaty? 'The world is safer today thanks to the leadership, collaboration and commitment of our Member States to adopt the historic WHO Pandemic Agreement,' said WHO Director-General Dr Tedros Adhanom Ghebreyesus in a statement. He added: 'The Agreement is a victory for public health, science and multilateral action. It will ensure we, collectively, can better protect the world from future pandemic threats. It is also a recognition by the international community that our citizens, societies and economies must not be left vulnerable to again suffer losses like those endured during Covid-19.'
&w=3840&q=100)
Business Standard
21-05-2025
- Business Standard
Alzheimer's diagnosis with blood test becomes reality: All you need to know
Lumipulse G pTau217/ß-Amyloid 1-42: USFDA has approved the first-ever blood test to help diagnose Alzheimer's disease, offering a faster, less invasive, and more affordable way to detect early signs Barkha Mathur New Delhi The US Food and Drug Administration (FDA) has approved the first-ever in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer's disease. Set to launch in June 2025, the test offers a faster, more accessible, and less invasive alternative to PET scans and spinal taps, especially for people showing early signs of memory loss and cognitive decline. It has been granted 'Breakthrough Device' designation by the FDA, reflecting its potential to significantly improve Alzheimer's detection and care. 'Alzheimer's disease impacts too many people, more than breast cancer and prostate cancer combined,' said FDA Commissioner Martin A Makary in a statement. 'Knowing that 10 per cent of people aged 65 and older have Alzheimer's, and that by 2050 that number is expected to double, I am hopeful that new medical products such as this one will help patients.' What is the Lumipulse blood test and how does it work? Developed by Fujirebio Diagnostics, the test is called the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio. It measures the ratio of two key biomarkers in the blood—β-amyloid 1-42 and β-amyloid 1-40—both of which are linked to the buildup of amyloid plaques in the brain, a defining feature of Alzheimer's disease. Who can take Alzheimer's blood test and when should it be used? The test is intended for adults aged 55 and older who are showing early signs of cognitive decline, such as memory loss or confusion. It is not a screening tool for asymptomatic individuals and is not available over the counter. The FDA emphasised that the test should support, not replace, a doctor's clinical assessment. It requires a physician's referral and is not meant for standalone diagnosis. What are the current ways Alzheimer's is diagnosed? Traditional diagnostic methods include: Cognitive tests and memory assessments Brain scans such as MRI or PET Spinal taps for cerebrospinal fluid (CSF) analysis These tests can be costly, invasive, and are not always covered by insurance—especially in developing countries. How accurate is the Alzheimer's blood test compared to current diagnostic methods? In a clinical trial involving 499 patients, the test demonstrated high diagnostic reliability: 91.7 per cent of people with positive results had Alzheimer's-associated plaques confirmed by PET scans or spinal taps 97.3 per cent of those with negative results had no plaques This level of accuracy could significantly reduce the need for expensive and invasive PET imaging or lumbar punctures. When and where will the Alzheimer's test be available? Fujirebio has confirmed that the test will be available in certified laboratories across the United States starting June 2025. It will not be sold directly to consumers and will require a physician's order. How can this test impact Alzheimer's treatment? Early diagnosis allows earlier intervention, which is critical to slowing the progression of Alzheimer's disease. This test could help doctors identify candidates for drugs like Leqembi (lecanemab) and Kisunla (donanemab) before significant brain damage occurs. A positive test result indicates the presence of amyloid plaques but does not confirm Alzheimer's on its own. False positives and negatives are possible, and results must be interpreted alongside other clinical evaluations. Why this matters for Alzheirmer's patients and caregivers This new blood test marks a significant breakthrough in making Alzheimer's diagnosis more accessible and less burdensome. For families and patients, it could mean earlier answers, targeted treatments, and improved planning for the future. For more health updates, follow #HealthWithBS
